RE:RE:RE:Knight wagyusteak wrote: Snowballgrowth wrote: mjn797979 wrote: I did message their investors relations and I got an answer back, Samira was very nice to answer.
I asked general questions about Grupo, its drugs, general guidance and she did give some answers.
Here is a brief recap:
-No financial guidance at this time due to effects of pandemic.
- They don't see an opportunity to cross polinate products from LATAM to Canada and vice versa
- Business dev. team is very busy looking to in-licence and acquire new products for Pan-American ex US territory.
- She underlined that GUD is a partnering organization and they will do what works best for them and partners.
- As far as valuation of Knight goes, she mentioned that they are going from being valued on their balance sheet to valued on their profitability.
- Samira ends by saying they are looking to grow Knight and expect that over time, shareholders will see the greater value.
I appreciate her detailed message, I think its the second time over the years she has replied back to my inquiry.
Lets hope, as current shareholders that we have better days ahead of us.
Thank you for sharing. I like this :
"As far as valuation of Knight goes, she mentioned that they are going from being valued on their balance sheet to valued on their profitability."
For those capable to see the profitability/ growth and pay the right price I guess ... they should make significant $.
I don't expect we make x100 times of our money like we did with Paladin labs in 20 years becasue we started GUD with a much larger capital base. But I think x50 is possible.
I don't know how you see a 50x from here. I'm curious to know. From what I hear most investors don't believe GUD will make $ 40 M ajusted earnings for the next 12 months.. and they made $ 10 M for the last quarter!!